A Randomised, Open-label, Three-part, Phase I Study to Determine the Effect of Food on the Pharmacokinetics of Olaparib and to Provide Data on the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 02 May 2017
At a glance
- Drugs Olaparib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 12 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 25 Mar 2016 Protocol amended as study design changed from single to parallel assignment as reported by ClinicalTrials.gov.
- 21 Sep 2014 Planned End Date changed from 1 Mar 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.